Adam S. Kibel, MD, presented “Neoadjuvant Therapy for High-Risk Prostate Cancer” during the 39th Annual Ralph E. Hopkins Urology Seminar on January 30th, 2019 in Jackson Hole, Wyoming.
How to cite: Kibel, Adam S. “Neoadjuvant Therapy for High-Risk Prostate Cancer” January 30, 2019. Accessed Nov 2024. https://grandroundsinurology.com/neoadjuvant-therapy-for-high-risk-prostate-cancer/
Neoadjuvant Therapy for High-Risk Prostate Cancer – Summary:
Adam S. Kibel, MD, argues that, while it is common to debate the best intervention method for local prostate cancer, there also must be an emphasis on the systemic treatment of micro-metastatic disease in the interest of decreasing disease-specific death. He then reviews the impact of timing, duration, and intensity of systemic therapy on patient outcomes, focusing on four trials evaluating neoadjuvant therapy for high-risk prostate cancer.
About the Ralph E. Hopkins Urology Seminar
The Ralph E. Hopkins Urology Seminar, or Jackson Hole Seminars (JHS), is a multi-day conference that focuses on patient safety and cutting-edge updates in the assessment, diagnosis, and treatment of urologic conditions. The topics discussed include urologic cancers, stone disease, urologic reconstruction, female urology, infertility, emerging surgical techniques, and general urology. In addition to didactic expert lectures, this conference features a unique interactive critique panel. Dr. Kibel presented this lecture during the 39th Annual JHS. Please visit this page in order to register for future JHS meetings.
ABOUT THE AUTHOR
Adam S. Kibel, MD, is currently serving as the Chief of Urology at Brigham and Women’s Hospital and Dana-Farber/Brigham and Women’s Cancer Center in Boston, Massachusetts. In addition, he is a Professor of Surgery at Harvard Medical School. Dr. Kibel graduated from Cornell University School of Medicine, then went on to complete his residency at Brigham and Women’s Hospital and a fellowship at Johns Hopkins.
Dr. Kibel has authored more than 300 peer-reviewed publications. In both his practice and research, he focuses on minimally invasive techniques to treat urologic cancers, including improved imaging and identification of molecular markers of urologic tumors. In 2019, Dr. Kibel was recognized as a Top Doctor by Boston Magazine and Castle Connolly.
